Impaired clearance of apoptotic cells results in the accumulation of secondary necrotic corpses, with profound immune consequences. Cell death triggers the macrophage inflammatory response, which normally contributes to tissue repair but under certain conditions can induce a state of chronic inflammation that is the basis of many diseases. Necrotic cells can also provoke an adaptive immune response via presentation of antigens by dendritic cells (DCs), and necrosis might explain adaptive immunity in seemingly infection-free situations, such as autoimmunity or spontaneous or therapy-induced tumour rejection. Myeloid C-type lectin receptors (CLRs), such as Mincle in macrophages and CLEC9A (DNGR-1) in DCs, have been identified as receptors for necrotic cells that couple to the tyrosine kinase Syk, which in turn can trigger innate and adaptive immune responses.
Our hypothesis is that recognition of cell death by Syk-coupled CLRs in myeloid cells might lie at the root of immune pathologies associated with an accumulation of dead cells. Our research program falls into three main strands. First, we are characterizing signaling and gene induction via CLEC9A as a model of innate sensing of necrotic cells by DCs. Second, we are investigating the role of Syk signaling and Syk-coupled receptors in myeloid cells in models of autoimmunity and of immune responses to dead tumor cells following a chemotherapy treatment. CLEC9A and Mincle are prime candidate mediators of the response to dead cells in DCs and macrophages, but our preliminary findings indicate that Syk deficiency has a more profound effect than CLEC9A deficiency on the sensing of necrosis by DCs, suggesting that additional receptors are involved. The third strand of our research is thus focused on the identification of new Syk-coupled receptors that recognize necrosis in myeloid cells.
David Sancho se graduó en Biología en la Universidad de Murcia (1995) y comenzó su carrera en inmunología como Biólogo Especialista en Inmunología vía B.I.R. en el Hospital de la Princesa de Madrid (2000). Su tesis doctoral (Departamento de Biología Molecular, UAM, Madrid, 2003) se centró en la función de la lectina tipo-C CD69, con especial hincapié en modelos de inflamación. Durante su periodo como investigador postdoctoral en el London Research Institute (Cancer Research UK, 2004-2009) descubrió un nuevo receptor lectina tipo-C expresado selectivamente en células dendríticas (CLEC9A, DNGR-1) y demostró su eficiencia en la vacunación anti-tumoral dirigida. Mediante la generación de ratones sin el receptor CLEC9A mostró que este receptor se relaciona con la respuesta inmune a células muertas. Este trabajo tiene posibles implicaciones en los orígenes de la inflamación crónica y de la autoinmunidad. Se incorporó al CNIC en septiembre 2009.